| Added by | mollevi |
|---|---|
| Last modified by | pmartino |
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination |
| Creator | Mbatchi et al. |
| Author | L. C. Mbatchi |
| Author | A. Schmitt |
| Author | F. Thomas |
| Author | Y. Cazaubon |
| Author | J. Robert |
| Author | S. Lumbroso |
| Author | J. P. Brouillet |
| Author | P. Pourquier |
| Author | E. Chatelut |
| Author | J. C. Boyer |
| Author | A. Evrard |
| Abstract | AIM: The goal of our study was to assess the impact of patients' genetic background on their sensitivity to carboplatin/paclitaxel hematotoxicity. PATIENTS & METHODS: Parameters describing sensitivity to neutropenia and to thrombocytopenia of 201 patients were extracted from a previous pharmacokinetic/pharmacodynamics analysis, in order to assess their association with 52 candidates SNPs in 18 genes. RESULTS: Carriers of a T allele of SLCO1B3-rs4149117 were 19% less sensitive to thrombocytopenia than the homozygotes for the G allele (p = 0.00279). Carriers of two copies of the ATG haplotypes of NR1I2-rs1523130, rs3814055 and rs1523127 were 19% less sensitive to thrombocytopenia than those harboring other haplotypes (p = 0.025). CONCLUSION: Our results revealed the importance of SLCO1B3 and NR1I2 in the sensitivity to carboplatin/paclitaxel thrombocytopenia. |
| Publication | Pharmacogenomics |
| Volume | 16 |
| Pages | 1439-50 |
| Date | Aug 2015 |
| Journal Abbr | Pharmacogenomics |
| DOI | 10.2217/pgs.15.84 |
| ISSN | 1744-8042 (Electronic) 1462-2416 (Linking) |
| Call Number | IMPACT: 2.302 |
| Extra | IMPACT: 2.302 |
| Tags | clinic, gso |
| Date Added | 2018/07/20 - 09:15:34 |
| Date Modified | 2019/06/11 - 10:07:41 |
| Notes and Attachments | (Note) (Note) (Note) (Note) 26267044 (Attachment) 26267044 (Attachment) |
Institut de Recherche en Cancérologie de
